BioSpace News Archive

Cytokinetics, Incorporated announced that members of its senior management will host an investor call at 8:30 AM Eastern Time on Wednesday, December 27, 2023 to discuss the topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten, an investigational medicine, in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Coherus BioSciences, Inc. announced that the U.S. Food and Drug Administration approved UDENYCA ONBODY™, the company’s on-body injector presentation of UDENYCA®, a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

SomaLogic, Inc., a leader in proteomics technology, issued the following statement in response to a press release issued by Madryn Asset Management, LP on December 26, 2023, regarding the pending merger with Standard BioTools.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023.

Procaps Group, S.A. announced its financial results for the three months ended September 30, 2023 and the nine months ended September 30, 2023.

Innovent Biologics, Inc. and Sanegene Bio USA Inc. announce that they have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen for the treatment of hypertension.

PharmaBlock Sciences, Inc., a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API GMP facility at its Zhejiang manufacturing site.

Caliway Biopharmaceuticals announced that the company will present at the 25th IMCAS World Congress on 1-3 February 2024 in Paris, France.

Everest Medicines announced that its New Drug Application for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration for the treatment of primary immunoglobulin A nephropathy in adult patients.